ReviewCell2025
Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy.
Review in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT07457424. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Direct Measurement of Changes in Food Selection and Intake Behaviour After Using the Maximum Dose of GLP-1 Receptor Agonists
Who cites it
30 citing papers in PubMed.
- Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs.World journal of methodology · 2026Review
- Global GPR75 deficiency protects against diet-induced obesity through central and peripheral mechanisms.Molecular metabolism · 2026Article
- Phytochemicals and Irisin as Multi-Target Regulators of Adipose Tissue Browning and Metabolic Reprogramming: Synergies with GLP-1 Pathways.Antioxidants (Basel, Switzerland) · 2026Review
- The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026Review
- NTS Neural Subtypes and Satiety Pathways: taVNS as a Novel Neuromodulatory Intervention.Brain sciences · 2026Review
- Generation of human appetite-regulating neurons and tanycytes from pluripotent stem cells.Cell stem cell · 2026Article
- Weight maintenance after discontinuation of GLP-1 therapies.EClinicalMedicine · 2026Review
- LEAP2 as a therapeutic target in obesity and cardiometabolic disorders.Reviews in endocrine & metabolic disorders · 2026Review
- Central nervous system adaptation mechanism of obesity induced by high-fat high-sucrose diet: Differences in brain function between obese and obese resistant rats based on fMRI.Metabolism open · 2026Article
- Neuronal glycogen powers anticipatory brain responses to food.Nature metabolism · 2026Article
- From diet to hypothalamic dysfunction: Neuroanatomical and hormonal integration of the microbiota-hypothalamus-adipose tissue axis.Reviews in endocrine & metabolic disorders · 2026Review
- BNC2 as a putative transcriptional coordinator linking energy state to neural circuits.iScience · 2026Review
- Cancer cachexia: A tumor-driven disorder of whole-body homeostasis.Cancer cell · 2026Review
- Hypothalamic orexigenic and anorexigenic neuropeptides in the rotenone model of Parkinson's disease.Scientific reports · 2026Article
- Hypothalamic regulation of sepsis-associated anorexia: cytokine and hormonal signalling through AgRP/POMC circuits.EMBO molecular medicine · 2026Review
- The Discovery of RGH-706, a Highly Efficacious MCH1 Receptor Antagonist, for the Treatment of Obesity and Insatiable Hunger.Journal of medicinal chemistry · 2026Article
- Microbiota-Gut-Brain Axis Disruption, Neuroinflammation, and Potential Antioxidant-Based Treatments in Metabolic Diseases.Antioxidants (Basel, Switzerland) · 2026Review
- A Preoptic Neuronal Population Regulates Energy Expenditure and Balance.bioRxiv : the preprint server for biology · 2026Article
- Perinatal liver sympathetic innervation governs body size.Communications biology · 2026Article
- Au clusterzymes encapsulated in nanogel activated by alternating magnetic field to promote white fat browning and combat obesity.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the evolution of hardwired homeostatic mechanisms to balance food intake with energy needs, the obesity epidemic continues to escalate globally. However, recent breakthroughs in delineating the molecular signaling pathways by which neural circuits regulate consummatory behaviors, along with transformative advances in peptide-based pharmacotherapy, are fueling the development of a new generation of safe and effective treatments for obesity. Here, we outline our current understanding of how the central nervous system controls energy homeostasis and examine how emerging insights, including those related to neuroplasticity, offer new perspectives for restoring energy balance and achieving durable weight loss. Together, these advances provide promising avenues for treating obesity and managing cardiometabolic disease.
Indexed as
Identifiers
40780185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.